We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Vertex: CF Drugs Nab First Two Breakthrough Therapy Designations
Vertex: CF Drugs Nab First Two Breakthrough Therapy Designations
January 11, 2013
Vertex’s cystic fibrosis (CF) drug Kalydeco and the combination regimen of VX-809 with Kalydeco have received the FDA’s first two breakthrough therapy designations, the company said Jan. 6.